Entrada Therapeutics Stock News

-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its 2026 DREAMS Grant Program: a competitive annual program that awards two $50,000 grants in supp...

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares of the Company's common stock to eight newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2...

-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 --  -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in ...

-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201  -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data fro...

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 18,600 restricted stock units (“RSUs”) to three newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of June 1, 2026. The inducement grants were previously approved by the Compensation Co...

ATLANTA, May 18, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Entrada Therapeutics, Inc. (“Entrada” or the “Company”) (NASDAQ: TRDA) complied with federal securities laws. On May 7, 2026, Entrada announced ELEVATE-44-201 cohort 1 topline results in its Duchenne muscular dystrophy study. Cohort 1 of the study demonstrated an increase of 2.36% in dystrophin, which fell b...

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Entrada Therapeutics, Inc. (NASDAQ: TRDA). The investigation focuses on Entrada's executive officers and whether investor losses may be recovered under federal securities laws.

Entrada Therapeutics NASDAQ: TRDA said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory patients with Duchenne muscular dystrophy, or DMD, who have mutations amenable to exon 44 skipping.